Centiva Capital’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Centiva Capital’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-140,393	Closed	-$1.41M	–	1758
2022 Q3	$1.41M	Hold	140,393	–	–	0.03%	476
2022 Q2	$1.39M	Buy	140,393 +6,544	+5%	+$64.7K	0.03%	480
2022 Q1	$1.32M	Buy	133,849 +29,542	+28%	+$290K	0.03%	601
2021 Q4	$1.02M	Hold	104,307	–	–	0.02%	598
2021 Q3	$1.02M	Hold	104,307	–	–	0.06%	331
2021 Q2	$1.03M	Sell	104,307 -400	-0.4%	-$3.94K	0.02%	558
2021 Q1	$1.04M	Buy	+104,707	New	+$1.08M	0.04%	331

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Centiva Capital's EUCR Position: Q4 2022 in Review

Centiva Capital sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 140,393 shares — an estimated $1.41M sold.

Centiva Capital first reported a position in EUCR in Q1 2021 and held it in 7 quarters. The position peaked at $1.41M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Centiva Capital reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Centiva Capital sold 140,393 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $1.41M.
Centiva Capital first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2021 and held it in 7 quarters.
Centiva Capital's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $1.41M in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Centiva Capital's 13F filing for Q4 2022, filed 14 Feb 2023.